Research programme: hair follicle-derived stem cell therapeutics - AntiCancer

Drug Profile

Research programme: hair follicle-derived stem cell therapeutics - AntiCancer

Alternative Names: DermaTek; Hair follicle pluripotent stem cells; hfPS; Lipo-4MA

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AntiCancer
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Stem cell growth factor agonists; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cardiovascular disorders
  • No development reported Acne; Alopecia; Neurological disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acne in USA (Topical)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alopecia(Chemotherapy-induced) in USA (Topical)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top